期刊文献+

岩舒对人大肠癌细胞株HCT8/VCR多药耐药的逆转作用及P糖蛋白表达的影响 被引量:4

REVERSAL OF MULTIDRUG RESISTANCE AND EXPRESSION OF P-GP ON HUMAN COLORECTAL CANCER CELL LINE HCT-8/VCR BY YANSU
下载PDF
导出
摘要 目的研究岩舒对大肠癌耐药细胞株HCT-8/VCR的逆转作用及P糖蛋白(P-gp)表达的影响。方法 MTT法测定岩舒含药血清对HCT-8/VCR细胞株的逆转作用,并以流式细胞仪测定P-gp的表达。结果经岩舒含药血清作用72 h后,HCT-8/VCR细胞株对化疗的耐药性显著下降,对长春新碱逆转指数为0.893±0.085,其逆转倍数大于13.7倍,与维拉帕米比较无统计学差异(p>0.05)。HCT-8/VCR细胞的P-gp表达显著高于HCT-8(p<0.01),经岩舒含药血清作用后P-gp表达显著降低(p<0.01)。结论岩舒可以逆转人大肠癌耐药细胞株HCT-8/VCR的多药耐药性,其机制可能与其下调P-gp的表达有关。 Objective To investigate the reversal effect of Yansu on muhidrug resistance of human colorectal cancer cell line HCT - 8/VCR and the impact of Yansu to the expressions of P - gp in HCT - 8/VCR. Methods The reversal effect of Yansu was observed by MTY assay, and the expressions of P - gp in HCT - 8/VCR cell line was detected with flow cytometry (FCM). Results After stimuhaneous treatment for 72 hours withYansu, the sensi- tivity of HCT -8/VCR rose significantly to VCR. The reversal index (RI)to VCR was 0. 893 ± 0. 085, and there are no statistical significance compared with VER group (p 〉0. 05). The P -gp had higher expression in HCT -8/VCR than in HCT - 8 (p 〈 0.01 ). It showed significant decrease after Yansu treatment (p 〈 0. 01 ). Conclusion Yansu can reverse the resistance of HCT - 8/VCR cel 1 1 ine. The mechanism may be related to the effect of down - regulation the expression of P - gp.
出处 《现代医院》 2012年第10期15-18,共4页 Modern Hospitals
基金 广东省中医药局科研立项课题(编号:2007211)
关键词 岩舒 多药耐药 大肠癌 P糖蛋白 Yansu, Muhidrug resistance, Colorectal cancer, P - glycprotein
  • 相关文献

参考文献17

  • 1黄吉雄,余晓红,蔡佩丽.大肠癌153例临床、肠镜及病理分析[J].现代医院,2008,8(3):26-28. 被引量:3
  • 2吴蓉,王志勇.染色内镜结合放大内镜对诊断和治疗大肠微小病变的价值[J].实用医学杂志,2010,26(23):4433-4435. 被引量:2
  • 3陈志霞,孔令春,孙玉舫,等.至真方对人大肠癌细胞株HCT8/VCR多药耐药的逆转作用及P-gp表达的影响[J].现代医学生物进展,2010,10(7) :1242-1246.
  • 4TSUKUMA H, AJIKI W. Descriptive epidemiology of colorectalcancer - international comparison[ J]. Nippon Rinsho, 2003,61 :25 -30.
  • 5LABIANCA H,M0SC0NI S’GARASSINO M C. New strategics incolon cancer adjuvant therapy [J]. Annals of Oncology, 2006, 17(7):51 -54.
  • 6LONGLCY D B,JOHNSTON P G. Molccular mcchanisms of drugrcsistancc[J].J Pathol ,2005,205(2) :275 -292.
  • 7WOODLAND C,KORCN G,WAINCR I W’et al. Verapamil me-tabolites ;potential P - glycoprotcin - mediated multidrug resis-tance reversal agents[ J]. Can J Physiol Pharmacol,2003 ,81 (8):800-805.
  • 8TAKAHA K,SAKACDA T,OKUMURA K. An update on overcom-ing MDR1 - mediated multidrug rcsistancc in canccr chemotherapy[J]. Curr Pharm(2006,12 (3) : 273 -286.
  • 9LABIALLC S, GAYCT L, MARTHINCT F,et al. Transcriptionalregulators of the human multidrug resistance 1 gene: recent views[J]. Biochemical pharmacology,2002,64(5 -6) : 943 -948.
  • 10SCHEFFER G L, KOOLM, HEUN M. Specific detection of mul-tidrug -resistance proteins MRP1,MRP2,MRP3,MRPS,andMDR3 P - glycoprotein with a panel of monoclonal antibodies[ J].Cancer Res, 2000,60:5269 -5277.

二级参考文献19

共引文献7

同被引文献76

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部